Movatterモバイル変換


[0]ホーム

URL:


US20070149522A1 - Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide - Google Patents

Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
Download PDF

Info

Publication number
US20070149522A1
US20070149522A1US10/538,342US53834203AUS2007149522A1US 20070149522 A1US20070149522 A1US 20070149522A1US 53834203 AUS53834203 AUS 53834203AUS 2007149522 A1US2007149522 A1US 2007149522A1
Authority
US
United States
Prior art keywords
chlorothiophene
carboxamide
oxo
reacting
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/538,342
Inventor
Christian Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AGfiledCriticalBayer Healthcare AG
Assigned to BAYER HEALTHCARE, AGreassignmentBAYER HEALTHCARE, AGASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: THOMAS, CHRISTIAN R.
Publication of US20070149522A1publicationCriticalpatent/US20070149522A1/en
Assigned to BAYER SCHERING PHARMA AGreassignmentBAYER SCHERING PHARMA AGMERGER (SEE DOCUMENT FOR DETAILS).Assignors: BAYER HEALTHCARE AG
Assigned to BAYER SCHERING PHARMA AGreassignmentBAYER SCHERING PHARMA AGCORRECTION IN COVER SHEET PREVIOUSLY RECORDEDAssignors: BAYER HEALTHCARE AG
Priority to US12/556,158priorityCriticalpatent/US8106192B2/en
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Definitions

Landscapes

Abstract

The invention relates to a method for producing 5-chloro-N-({5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide starting from 5-chlorothiophene-2-carbonyl chloride, (2S)-3-amino-propane-1,2-diol and 4-(4-aminophenyl)-3-morpholinone.

Description

Claims (16)

Figure US20070149522A1-20070628-C00011
comprising
preparing 5-chlorothiophene-2-carbonyl chloride (IV) in a first step by chlorinating 5-chlorothiophene-2-carboxylic acid;
reacting said 5-chlorothiophene-2-carbonyl chloride (IV) in a second step with (2S)-3-aminopropane-1,2-diol hydrochloride (VII) to give N—((S)-2,3-dihydroxypropyl)-5-chlorothiophene-2-carboxamide (VIII);
converting said N—((S)-2,3-dihydroxypropyl)-5-chlorothiophene-2-carboxamide (VIII) in a third step to N—((S)-3-bromo-2-hydroxypropyl)-5-chlorothiophene-2-carboxamide (IX);
converting said N—((S)-3-bromo-2-hydroxypropyl)-5-chlorothiophene-2-carboxamide (IX) in a fourth step by reacting with 4-(4-aminophenyl)-3-morpholinone (III) to N—{(R)-2-hydroxy-3-[4-(3-oxomorpholin-4-yl)phenylamino]propyl}-5-chlorothiophene-2-carboxamide (X);
reacting said N—{(R)-2-hydroxy-3-[4-(3-oxomorpholin-4-yl)phenylamino]propyl}-5-chlorothiophene-2-carboxamide (X) in a fifth step with phosgene or a phosgene equivalent.
11. The process ofclaim 10, further comprising preparing said N—((S)-2,3-dihydroxypropyl)-5-chlorothiophene-2-carboxamide (VIII) by reacting 5-chlorothiophene-2-carbonyl chloride (IV) with (2S)-3-aminopropane-1,2-diol hydrochloride (VII).
12. N—{(R)-2-Hydroxy-3-[4-(3-oxomorpholin-4-yl)phenylamino]propyl}-5-chlorothiophene-2-carboxamide of the formula (X)
Figure US20070149522A1-20070628-C00012
US10/538,3422003-01-072003-12-24Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamideAbandonedUS20070149522A1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US12/556,158US8106192B2 (en)2003-01-072009-09-09Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
DE10300111.52003-01-07
DE10300111ADE10300111A1 (en)2003-01-072003-01-07 Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide
PCT/EP2003/014871WO2004060887A1 (en)2003-01-072003-12-24Method for producing 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
PCT/EP2003/014871A-371-Of-InternationalWO2004060887A1 (en)2003-01-072003-12-24Method for producing 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
US12/556,158DivisionUS8106192B2 (en)2003-01-072009-09-09Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide

Publications (1)

Publication NumberPublication Date
US20070149522A1true US20070149522A1 (en)2007-06-28

Family

ID=32519617

Family Applications (2)

Application NumberTitlePriority DateFiling Date
US10/538,342AbandonedUS20070149522A1 (en)2003-01-072003-12-24Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
US12/556,158Expired - LifetimeUS8106192B2 (en)2003-01-072009-09-09Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
US12/556,158Expired - LifetimeUS8106192B2 (en)2003-01-072009-09-09Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide

Country Status (8)

CountryLink
US (2)US20070149522A1 (en)
EP (1)EP1583761B1 (en)
JP (1)JP4667044B2 (en)
AU (1)AU2003296728A1 (en)
CA (1)CA2512504C (en)
DE (2)DE10300111A1 (en)
ES (1)ES2360097T3 (en)
WO (1)WO2004060887A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040242660A1 (en)*2001-06-202004-12-02Alexander StraubSubstituted oxazolidinones for combinational therapy
US20070026065A1 (en)*2004-12-242007-02-01Bayer Healthcare AgSolid, modified-release pharmaceutical dosage forms which can be administered orally
US20080090815A1 (en)*1999-12-242008-04-17Alexander StraubSubstituted oxazolidinones and their use in the field of blood coagulation
US20080306070A1 (en)*2005-10-042008-12-11Bayer Healthcare AgCombination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders
US20090004265A1 (en)*2005-01-312009-01-01Bayer Healthcare AgPrevention and Treatment of Thromboembolic Disorders
US20090036504A1 (en)*2005-09-232009-02-05Bayer Healthcare Ag2-Aminoethoxyacetic Acid Derivatives and Their Use
US20090048173A1 (en)*2004-05-132009-02-19Wolfgang EisertUse Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors
US20100081807A1 (en)*2003-01-072010-04-01Bayer Healthcare AgMethod for producing 5-cloro-n-(methyl)-2-thiophenecarboxamide
US20100120718A1 (en)*2006-11-022010-05-13Bayer Schering Pharma AktiengesellschaftCombination therapy of substituted oxazolidinones
US20100152189A1 (en)*2005-10-042010-06-17Bayer Healthcare AgNovel polymorphous form and the amorphous form of 5-chloro-n-({ (5s)-2-oxo-3[4-(3-oxo-4-morpholinyl(-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
US7816355B1 (en)2009-04-282010-10-19Apotex Pharmachem IncProcesses for the preparation of rivaroxaban and intermediates thereof
WO2012051692A1 (en)2010-10-182012-04-26Apotex Pharmachem Inc.Processes for the preparation of rivaroxaban and intermediates thereof
CN102753537A (en)*2010-02-102012-10-24桑多斯股份公司Method for the preparation of rivaroxaban
CN102822167A (en)*2010-01-042012-12-12埃南蒂亚有限公司Process for the preparation of rivaroxaban and intermediates thereof
WO2013152168A1 (en)2012-04-062013-10-10Indiana University Research And Technology CorporationProcesses for preparing rivaroxaban
CN103351385A (en)*2013-06-282013-10-16浙江燎原药业有限公司Preparation method for rivaroxaban intermediate
WO2013164833A1 (en)*2012-05-022013-11-07Symed Labs LimitedImproved process for preparing rivaroxaban using novel intermediates
US8586082B2 (en)2005-10-042013-11-19Bayer Intellectual Property GmbhSolid orally administerable pharmaceutical dosage forms with rapid active principle release
CN103524447A (en)*2013-10-242014-01-22山东铂源药业有限公司Method for synthesizing rivaroxaban intermediate 4-(4-aminophenyl)-3-molindone
CN103724336A (en)*2013-12-242014-04-16悦康药业集团有限公司Synthesis method of novel anticoagulation drug
CN103864771A (en)*2012-12-132014-06-18北京京卫信康医药科技发展有限公司Rivaroxaban preparation method
WO2016045586A1 (en)*2014-09-262016-03-31华北制药集团新药研究开发有限责任公司Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof
US9402851B2 (en)2003-11-272016-08-02Bayer Intellectual Property GmbhProcess for the preparation of a solid, orally administrable pharmaceutical composition
US9556163B2 (en)2011-05-062017-01-31Egis Gyogyszergyar Nyilvanosan Mukodo ReszvenytarsasagProcess for the preparation of a rivaroxaban and intermediates formed in said process
CN109280053A (en)*2018-10-112019-01-29东南大学 Rivaroxaban oxazolidine impurity reference substance and preparation method thereof
WO2020101587A1 (en)2018-11-162020-05-22Santa Farma İlaç Sanayi̇ A.Ş.Oral formulations comprising rivaroxaban

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE102004002044A1 (en)*2004-01-152005-08-04Bayer Healthcare Ag manufacturing
EP1571154A1 (en)*2004-03-032005-09-07Aventis Pharma Deutschland GmbHBeta-aminoacid-derivatives as factor Xa inhibitors
DE102005047564A1 (en)*2005-10-042007-05-31Bayer Healthcare AgNew forms of specific substituted thiophene carboxamide (rivaroxaban), useful for prevention and treatment of thromboembolic disease, have higher solubility than known modifications
DE102007028320A1 (en)2007-06-202008-12-24Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007032347A1 (en)2007-07-112009-01-15Bayer Healthcare Ag Aminoacyl prodrugs
DE102007032345A1 (en)2007-07-112009-01-15Bayer Healthcare Ag Aminoacyl prodrugs
WO2009018807A1 (en)*2007-08-062009-02-12Schebo Biotech AgNovel pharmaceuticals, method for the production thereof, and use thereof in therapy
DE102007037373A1 (en)2007-08-062009-02-19Schebo Biotech AgNew oxazolidinone derivatives are factor Xa inhibitors useful to treat e.g. acute coronary syndrome, myocardial infarction, angina pectoris, reocclusion, restenosis, stroke, artrial fibrillation, arrhythmia and blood clotting disorder
US20100168111A1 (en)*2008-12-312010-07-01Apotex Pharmachem Inc.Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
SI2459555T1 (en)2009-07-312022-03-31Krka, D.D., Novo MestoProcesses for crystallization of rivaroxaban
EP2404920A1 (en)2010-07-062012-01-11Sandoz AGCrystalline form of Rivaroxaban dihydrate
CN104693139B (en)*2011-01-072017-04-19浙江九洲药业股份有限公司Novel technology for synthesizing Rivaroxaban intermediate
US9221771B2 (en)2011-04-112015-12-29Sandoz AgMethod for the preparation of substituted oxazolidinones
ES2395304B1 (en)2011-05-202014-01-16Interquim, S.A. PROCEDURE FOR OBTAINING A THIOPHEN-2-CARBOXAMIDE.
WO2013098833A2 (en)2011-09-082013-07-04Cadila Healthcare LimitedProcesses and intermediates for preparing rivaroxaban
HU230734B1 (en)2011-10-102017-12-28EGIS Gyógyszergyár NyrtCocrystals of rivaroxaban for producing pharmaceutical compositions
CZ2012111A3 (en)2012-02-162013-08-28Zentiva, K.S.Process for preparing rivaroxaban based on the use of (S)-epichlorohydrin
CZ2012114A3 (en)2012-02-172013-02-20Zentiva, K.S.Process for preparing rivaroxaban based on saving of 1,1?-carbonyldiimidazole
CN103288814B (en)2012-02-242016-07-06国药集团国瑞药业有限公司A kind of preparation method of Rivaroxaban intermediate
SG11201406623PA (en)*2012-04-162014-11-27Ranbaxy Lab LtdProcess for the preparation of rivaroxaban and intermediates thereof
US20150133657A1 (en)*2012-05-242015-05-14Ranbaxy Laboratories LimitedProcess for the preparation of rivaroxaban
IN2015DN02600A (en)2012-09-262015-09-18Ranbaxy Lab Ltd
SI2935255T1 (en)2012-12-212018-01-31Farma Grs, D. O. O.A process for preparation of rivaroxaban
MX2015003319A (en)2012-12-262015-08-14Wanbury LtdAldehyde derivative of substitute oxazolidinones.
EP2895176B1 (en)2012-12-262016-10-19Wanbury LimitedRivaroxaban intermediate and preparation thereof
WO2014155259A2 (en)2013-03-252014-10-02Glenmark Pharmaceuticals Limited; Glenmark Generics LimitedProcess for the preparation of rivaroxaban
WO2015011617A1 (en)2013-07-232015-01-29Ranbaxy Laboratories LimitedProcess for the preparation of rivaroxaban
IN2013MU02699A (en)*2013-08-192015-06-19Amneal Pharmaceuticals Llc
CN104098558B (en)*2014-07-222016-07-06常州市第四制药厂有限公司Amides compound and preparation method thereof
US20170267669A1 (en)2014-08-252017-09-21Cipla LimitedProcess for the Preparation of Rivaroxaban
PL3209661T3 (en)2014-10-222021-08-16Zakłady Farmaceutyczne Polpharma SaProcess for preparing a polymorph of rivaroxaban
KR101811123B1 (en)2016-02-192017-12-20일동제약(주)Novel morpholine diphosphate salt, and method for manufacturing high purity rivaroxaban using same
CN109481445A (en)*2018-12-192019-03-19黄泳华Composition containing morpholine ketone compounds
GB202102575D0 (en)2021-02-232021-04-07Teva Pharmaceutical Industries LtdFixed-dose pharmaceutical compositions
EP4434983A4 (en)2021-11-172025-02-26Zhejiang Huahai Pharmaceutical Co., Ltd. PROCESS FOR THE SYNTHESIS OF RIVAROXABAN
EP4201933A1 (en)2021-12-232023-06-28Zaklady Farmaceutyczne Polpharma S.A.Crystallisation process for rivaroxaban

Citations (53)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2811555A (en)*1955-05-021957-10-29Eastman Kodak CoReduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en)*1965-07-121966-10-18Eastman Kodak CoPolyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
US4128654A (en)*1978-02-101978-12-05E. I. Du Pont De Nemours And Company5-Halomethyl-3-phenyl-2-oxazolidinones
US4250318A (en)*1977-08-261981-02-10Delalande S.A.Novel 5-hydroxymethyl oxazolidinones, the method of preparing them and their application in therapeutics
US4327725A (en)*1980-11-251982-05-04Alza CorporationOsmotic device with hydrogel driving member
US4500519A (en)*1978-11-061985-02-19Choay S.A.Mucopolysaccharides having biological properties, preparation and method of use
US4705779A (en)*1983-03-111987-11-10Biogal Gyogyszergyar Of Debrecen And Alkaloida Vegyeszeti Gyar Of TiszavasvariPharmaceutical compositions of anti-pancreatic inflammatory effect
US4765989A (en)*1983-05-111988-08-23Alza CorporationOsmotic device for administering certain drugs
US4948801A (en)*1988-07-291990-08-14E. I. Du Pont De Nemours And CompanyAminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4977173A (en)*1987-10-211990-12-11E. I. Du Pont De Nemours And CompanyAminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
US5002937A (en)*1988-07-051991-03-26Boehringer Mannheim GmbhDiphosphonic acid compounds and use for calcium metabolism disorders
US5254577A (en)*1988-07-291993-10-19The Du Pont Merck Pharmaceutical CompanyAminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5349045A (en)*1993-01-261994-09-20United States Surgical CorporationPolymer derived from cyclic amide and medical devices manufactured therefrom
US5532255A (en)*1993-05-011996-07-02Merck Patent Gesellschaft Mit Beschrankter HaftungAdhesion receptor antagonists
US5561148A (en)*1993-09-231996-10-01Merck Patent Gesellschaft Mit Beshrankter HaftungAdhesion receptor antagonists III
US5654428A (en)*1991-11-011997-08-05Pharmacia & Upjohn CompanySubstituted heteroarylphenyloxazolidinones
US5656571A (en)*1995-04-051997-08-12Deerpoint Industries, Inc.Polyolefinic adjuvants
US5688792A (en)*1994-08-161997-11-18Pharmacia & Upjohn CompanySubstituted oxazine and thiazine oxazolidinone antimicrobials
US5792765A (en)*1996-02-061998-08-11Bayer AktiengesellschaftSubstituted oxazolidinones
US5827857A (en)*1996-01-161998-10-27Bayer AktiengesellschaftPyrido-fused thienyl- and furanyl-oxazolidinones
US5910504A (en)*1995-02-031999-06-08Pharmacia & UpjohnHetero-aromatic ring substituted phenyloxazolidinone antimicrobials
US5922708A (en)*1996-02-061999-07-13Bayer AktiengesellschaftHeteroaryl-oxazolidinones
US5935724A (en)*1997-04-041999-08-10Wilson Greatbatch Ltd.Electrochemical cell having multiplate electrodes with differing discharge rate regions
US5972947A (en)*1995-07-071999-10-26Roche Diagnostics GmbhOxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds
US5977373A (en)*1997-07-111999-11-02Pharmacia & Upjohn CompanyThiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
US5998406A (en)*1997-11-121999-12-07Pharmacia & Upjohn CompanyOxazolidinone derivatives and pharmaceutical compositions
US6069160A (en)*1995-04-212000-05-30Bayer AktiengesellschaftHeteroatom-containing benzocyclopentane-oxazolidinones
US6218413B1 (en)*1997-05-302001-04-17Pharmacia & Upjohn CompanyOxazolidinone antibacterial agents having a thiocarbonyl functionality
US6251869B1 (en)*1998-05-182001-06-26Pharmacia & Upjohn CompanyEnhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
US6265178B1 (en)*1997-12-052001-07-24Pharmacia & Upjohn CompanyAssay for determining oxazolidinone antibiotics having minimum monoamine oxidase inhibitory activity
US6281210B1 (en)*1999-12-142001-08-28Pharmacia & Upjohn CompanyBenzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent
US6294201B1 (en)*1997-10-122001-09-25Bayer AktiengesellschaftOsmotic medicament releasing system
US20010029351A1 (en)*1998-04-162001-10-11Robert FaloticoDrug combinations and delivery devices for the prevention and treatment of vascular disease
US20010046987A1 (en)*1999-12-212001-11-29Hester Jackson B.Oxazolidinones having a sulfoximine functionality
US6458793B1 (en)*1997-07-292002-10-01Zeneca LimitedHeterocyclic derivatives which inhibit factor Xa
US20030153610A1 (en)*1999-12-242003-08-14Alexander StraubSubstituted oxazolidinones and their in the field of blood coagulation
US20030161882A1 (en)*2002-02-012003-08-28Waterman Kenneth C.Osmotic delivery system
US20040102450A1 (en)*1998-01-272004-05-27Aventis Pharmaceuticals Inc.Substituted oxoazaheterocyclyl compounds
US20040162427A1 (en)*2001-03-072004-08-19Ulrich RosentreterSubstituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands
US6805881B1 (en)*1998-09-182004-10-19Bayer AktiengesellschaftMultiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
US6818243B2 (en)*1999-12-282004-11-16Ajinomoto Co., Inc.Crystals of aspartame derivative
US20040242660A1 (en)*2001-06-202004-12-02Alexander StraubSubstituted oxazolidinones for combinational therapy
US20050064006A1 (en)*2001-10-242005-03-24Bayer AktiengesellschaftStents
US20050182055A1 (en)*2004-01-152005-08-18Bayer Healthcare AgPreparation process
US20050261502A1 (en)*2001-03-052005-11-24Ulrich RosentreterSubstituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof
US7034017B2 (en)*2001-02-092006-04-25Bayer AktiengesellschaftSubstituted oxazolidinones and their use in the field of blood coagulation
US7045631B2 (en)*2001-07-162006-05-16Bayer AktiengesellschaftSubstituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands
US20060154969A1 (en)*2001-03-072006-07-13Ulrich RosentreterAdenosine receptor selective modulators
US7078417B2 (en)*2001-03-302006-07-18Bayer AktiengesellschaftSubstituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
US7109218B2 (en)*2001-12-112006-09-19Bayer Healthcare AgSubstituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
US7129255B2 (en)*2001-03-302006-10-31Bayer AktiengesellschaftSubstituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor
US20070026065A1 (en)*2004-12-242007-02-01Bayer Healthcare AgSolid, modified-release pharmaceutical dosage forms which can be administered orally
US20080026057A1 (en)*2003-11-272008-01-31Bayer Healthcare AgProcess for the Preparation of a Solid, Orally Administrable Pharmaceutical Composition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4259201A (en)*1979-11-091981-03-31The Procter & Gamble CompanyDetergent composition containing organic peracids buffered for optimum performance
NZ206600A (en)1983-05-111987-01-23Alza CorpOsmotic drug delivery device
ES533097A0 (en)1983-06-071985-08-01Du Pont A PROCEDURE FOR THE PREPARATION OF NEW AMINO-METHYL-OXOOXAZOLIDINYL-BENZENE DERIVATIVES.
DE3884563T2 (en)1987-10-211994-02-17Du Pont Merck Pharma Aminomethyl oxo oxazolidinyl ethenyl benzene derivatives useful as an antibacterial agent.
US5139788A (en)*1989-10-171992-08-18Ecolab Inc.Noncontaminating antimicrobial composition
US5264229A (en)*1992-04-201993-11-23Degussa CorporationShelf life extension for commercially processed poultry/fowl and seafood products using a specialized hydrogen peroxide
SK283420B6 (en)1992-05-082003-07-01Pharmacia & Upjohn Company Antimicrobial oxazolidinones containing substituted diazine groups
JP3255499B2 (en)*1993-06-162002-02-12花王株式会社 Novel sulfonate, process for producing the same, and bleach composition containing the same
US5362899A (en)*1993-09-091994-11-08Affymax Technologies, N.V.Chiral synthesis of alpha-aminophosponic acids
US5374369A (en)*1993-10-141994-12-20Lever Brothers Company, Division Of Conopco, Inc.Silver anti-tarnishing detergent composition
US5683977A (en)*1995-03-061997-11-04Lever Brothers Company, Division Of Conopco, Inc.Dry cleaning system using densified carbon dioxide and a surfactant adjunct
US5698506A (en)*1995-05-191997-12-16Lever Brothers Company, Division Of Conopco, Inc.Automatic dishwashing compositions containing aluminum salts
RU2175324C2 (en)1995-09-012001-10-27Фармация Энд Апджон КомпаниPhenyloxazolidinones having c-c-bond with 4-8-membered heterocyclic rings
DE69631347T2 (en)1995-09-152004-10-07Upjohn Co AMINOARYL OXAZOLIDINONE N-OXIDES
US6310025B1 (en)*1996-03-042001-10-30The Procter & Gamble CompanyLaundry pretreatment process and bleaching compositions
US5968885A (en)*1996-04-221999-10-19Procter & Gamble Co.Bleaching compositions
MA25183A1 (en)*1996-05-172001-07-02Arthur Jacques Kami Christiaan DETERGENT COMPOSITIONS
GB9614238D0 (en)1996-07-061996-09-04Zeneca LtdChemical compounds
ES2232873T3 (en)1996-07-152005-06-01Sankyo Company Limited PHARMACEUTICAL COMPOSITIONS INCLUDING THE CS-866 AND OTHER AGENTS THAT IMPROVE INSULIN RESISTANCE AND ITS USE FOR THE TREATMENT OF ARTEROSCLEROSIS AND XANTOMA.
US6273913B1 (en)1997-04-182001-08-14Cordis CorporationModified stent useful for delivery of drugs along stent strut
DE19730847A1 (en)1997-07-181999-01-28Bayer Ag Tricyclically substituted oxazolidinones
US6444634B1 (en)*1997-09-112002-09-03The Procter & Gamble CompanyBleaching compositions
DE19755268A1 (en)1997-12-121999-06-17Merck Patent Gmbh Benzamidine derivatives
DE19802239A1 (en)1998-01-221999-07-29Bayer AgNew oxazolidinone derivatives useful as antimicrobial agents against Gram-positive and some Gram-negative bacteria, mycobacteria, etc.
US6239152B1 (en)1998-01-232001-05-29Pharmacia & Upjohn CompanyOxazolidinone combinatorial libraries, compositions and methods of preparation
DE19805117A1 (en)1998-02-091999-08-12Bayer Ag New oxazolidinones with azole-containing tricycles
US6346279B1 (en)*1998-12-142002-02-12Virox Technologies, Inc.Hydrogen peroxide disinfectant with increased activity
US6740126B2 (en)*2000-02-152004-05-25Strike Investments, LlcMethod for the application of durable press finishes to textile components via the use of hydrophobic bleaching preparation
WO2001064993A1 (en)*2000-02-152001-09-07The Procter & Gamble CompanyMethod for the one step preparation of textiles
US6830591B1 (en)*2000-02-152004-12-14The Procter & Gamble CompanyMethod for the use of hydrophobic bleaching systems in textile preparation
DE10300111A1 (en)2003-01-072004-07-15Bayer Healthcare Ag Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide
EP1685841A1 (en)2005-01-312006-08-02Bayer Health Care AktiengesellschaftPrevention and treatment of thromboembolic disorders
US7754670B2 (en)*2005-07-062010-07-13Ecolab Inc.Surfactant peroxycarboxylic acid compositions
DE102005045518A1 (en)2005-09-232007-03-29Bayer Healthcare AgNew 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa
EP1934208B1 (en)2005-10-042011-03-23Bayer Schering Pharma AktiengesellschaftNovel polymorphous form of 5-chloro-n-({ (5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (en)2005-10-042007-04-05Bayer Healthcare AgDrug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
DE102005047558A1 (en)2005-10-042008-02-07Bayer Healthcare Ag Combination therapy of substituted oxazolidinones for the prophylaxis and treatment of cerebral circulatory disorders
DE102005048824A1 (en)2005-10-102007-04-12Bayer Healthcare Ag Treatment and prophylaxis of microangiopathies

Patent Citations (62)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2811555A (en)*1955-05-021957-10-29Eastman Kodak CoReduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en)*1965-07-121966-10-18Eastman Kodak CoPolyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
US4250318A (en)*1977-08-261981-02-10Delalande S.A.Novel 5-hydroxymethyl oxazolidinones, the method of preparing them and their application in therapeutics
US4128654A (en)*1978-02-101978-12-05E. I. Du Pont De Nemours And Company5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en)*1978-11-061985-02-19Choay S.A.Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en)*1980-11-251982-05-04Alza CorporationOsmotic device with hydrogel driving member
US4705779A (en)*1983-03-111987-11-10Biogal Gyogyszergyar Of Debrecen And Alkaloida Vegyeszeti Gyar Of TiszavasvariPharmaceutical compositions of anti-pancreatic inflammatory effect
US4765989A (en)*1983-05-111988-08-23Alza CorporationOsmotic device for administering certain drugs
US4977173A (en)*1987-10-211990-12-11E. I. Du Pont De Nemours And CompanyAminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
US5002937A (en)*1988-07-051991-03-26Boehringer Mannheim GmbhDiphosphonic acid compounds and use for calcium metabolism disorders
US4948801A (en)*1988-07-291990-08-14E. I. Du Pont De Nemours And CompanyAminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en)*1988-07-291993-10-19The Du Pont Merck Pharmaceutical CompanyAminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5801246A (en)*1991-11-011998-09-01Pharmacia & Upjohn CompanySubstituted heteroarylphenyloxazolidinones
US5654428A (en)*1991-11-011997-08-05Pharmacia & Upjohn CompanySubstituted heteroarylphenyloxazolidinones
US5654435A (en)*1991-11-011997-08-05Pharmacia & Upjohn CompanySubstituted arylphenyloxazolindinones
US5756732A (en)*1991-11-011998-05-26Pharmacia & Upjohn CompanySubstituted heteroarylphenyloxazolidinones
US5929248A (en)*1991-11-011999-07-27Pharmacia & Upjohn CompanySubstituted heteroarylphenyloxazolidinones
US5349045A (en)*1993-01-261994-09-20United States Surgical CorporationPolymer derived from cyclic amide and medical devices manufactured therefrom
US5532255A (en)*1993-05-011996-07-02Merck Patent Gesellschaft Mit Beschrankter HaftungAdhesion receptor antagonists
US5561148A (en)*1993-09-231996-10-01Merck Patent Gesellschaft Mit Beshrankter HaftungAdhesion receptor antagonists III
US5688792A (en)*1994-08-161997-11-18Pharmacia & Upjohn CompanySubstituted oxazine and thiazine oxazolidinone antimicrobials
US5910504A (en)*1995-02-031999-06-08Pharmacia & UpjohnHetero-aromatic ring substituted phenyloxazolidinone antimicrobials
US5656571A (en)*1995-04-051997-08-12Deerpoint Industries, Inc.Polyolefinic adjuvants
US6069160A (en)*1995-04-212000-05-30Bayer AktiengesellschaftHeteroatom-containing benzocyclopentane-oxazolidinones
US5972947A (en)*1995-07-071999-10-26Roche Diagnostics GmbhOxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds
US5827857A (en)*1996-01-161998-10-27Bayer AktiengesellschaftPyrido-fused thienyl- and furanyl-oxazolidinones
US5922708A (en)*1996-02-061999-07-13Bayer AktiengesellschaftHeteroaryl-oxazolidinones
US5792765A (en)*1996-02-061998-08-11Bayer AktiengesellschaftSubstituted oxazolidinones
US5935724A (en)*1997-04-041999-08-10Wilson Greatbatch Ltd.Electrochemical cell having multiplate electrodes with differing discharge rate regions
US6218413B1 (en)*1997-05-302001-04-17Pharmacia & Upjohn CompanyOxazolidinone antibacterial agents having a thiocarbonyl functionality
US5977373A (en)*1997-07-111999-11-02Pharmacia & Upjohn CompanyThiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
US6458793B1 (en)*1997-07-292002-10-01Zeneca LimitedHeterocyclic derivatives which inhibit factor Xa
US6294201B1 (en)*1997-10-122001-09-25Bayer AktiengesellschaftOsmotic medicament releasing system
US5998406A (en)*1997-11-121999-12-07Pharmacia & Upjohn CompanyOxazolidinone derivatives and pharmaceutical compositions
US6265178B1 (en)*1997-12-052001-07-24Pharmacia & Upjohn CompanyAssay for determining oxazolidinone antibiotics having minimum monoamine oxidase inhibitory activity
US20040102450A1 (en)*1998-01-272004-05-27Aventis Pharmaceuticals Inc.Substituted oxoazaheterocyclyl compounds
US20010029351A1 (en)*1998-04-162001-10-11Robert FaloticoDrug combinations and delivery devices for the prevention and treatment of vascular disease
US6251869B1 (en)*1998-05-182001-06-26Pharmacia & Upjohn CompanyEnhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
US6805881B1 (en)*1998-09-182004-10-19Bayer AktiengesellschaftMultiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
US6281210B1 (en)*1999-12-142001-08-28Pharmacia & Upjohn CompanyBenzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent
US20010046987A1 (en)*1999-12-212001-11-29Hester Jackson B.Oxazolidinones having a sulfoximine functionality
US20080200674A1 (en)*1999-12-242008-08-21Bayer Healthcare AktiengesellschaftSubstituted oxazolidinones and their use in the field of blood coagulation
US20080090815A1 (en)*1999-12-242008-04-17Alexander StraubSubstituted oxazolidinones and their use in the field of blood coagulation
US7157456B2 (en)*1999-12-242007-01-02Bayer Healthcare AgSubstituted oxazolidinones and their use in the field of blood coagulation
US20060258724A1 (en)*1999-12-242006-11-16Alexander StraubSubstituted Oxazolidinones and Their Use in the Field of Blood Coagulation
US20030153610A1 (en)*1999-12-242003-08-14Alexander StraubSubstituted oxazolidinones and their in the field of blood coagulation
US6818243B2 (en)*1999-12-282004-11-16Ajinomoto Co., Inc.Crystals of aspartame derivative
US7034017B2 (en)*2001-02-092006-04-25Bayer AktiengesellschaftSubstituted oxazolidinones and their use in the field of blood coagulation
US20050261502A1 (en)*2001-03-052005-11-24Ulrich RosentreterSubstituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof
US20040162427A1 (en)*2001-03-072004-08-19Ulrich RosentreterSubstituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands
US20060154969A1 (en)*2001-03-072006-07-13Ulrich RosentreterAdenosine receptor selective modulators
US7129255B2 (en)*2001-03-302006-10-31Bayer AktiengesellschaftSubstituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor
US7078417B2 (en)*2001-03-302006-07-18Bayer AktiengesellschaftSubstituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
US20040242660A1 (en)*2001-06-202004-12-02Alexander StraubSubstituted oxazolidinones for combinational therapy
US7045631B2 (en)*2001-07-162006-05-16Bayer AktiengesellschaftSubstituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands
US20050064006A1 (en)*2001-10-242005-03-24Bayer AktiengesellschaftStents
US7109218B2 (en)*2001-12-112006-09-19Bayer Healthcare AgSubstituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
US20030161882A1 (en)*2002-02-012003-08-28Waterman Kenneth C.Osmotic delivery system
US20080026057A1 (en)*2003-11-272008-01-31Bayer Healthcare AgProcess for the Preparation of a Solid, Orally Administrable Pharmaceutical Composition
US20050182055A1 (en)*2004-01-152005-08-18Bayer Healthcare AgPreparation process
US7351823B2 (en)*2004-01-152008-04-01Bayer Healthcare AgPreparation process
US20070026065A1 (en)*2004-12-242007-02-01Bayer Healthcare AgSolid, modified-release pharmaceutical dosage forms which can be administered orally

Cited By (50)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7585860B2 (en)1999-12-242009-09-08Bayer Schering Pharma AktiengesellschaftSubstituted oxazolidinones and their use in the field of blood coagulation
US8129378B2 (en)1999-12-242012-03-06Bayer Pharma AktiengesellschaftSubstituted oxazolidinones and their use in the field of blood coagulation
US20080090815A1 (en)*1999-12-242008-04-17Alexander StraubSubstituted oxazolidinones and their use in the field of blood coagulation
US20080200674A1 (en)*1999-12-242008-08-21Bayer Healthcare AktiengesellschaftSubstituted oxazolidinones and their use in the field of blood coagulation
US8530505B2 (en)1999-12-242013-09-10Bayer Intellectual Property GmbhSubstituted oxazolidinones and their use in the field of blood coagulation
US8822458B2 (en)1999-12-242014-09-02Bayer Intellectual Property GmbhSubstituted oxazolidinones and their use in the field of blood coagulation
US20100137274A1 (en)*1999-12-242010-06-03Bayer Schering Pharma AgSubstituted oxazolidinones and their use in the field of blood coagulation
US7592339B2 (en)1999-12-242009-09-22Bayer Schering Pharma AktiengesellschaftSubstituted oxazolidinones and their use in the field of blood coagulation
US7576111B2 (en)1999-12-242009-08-18Bayer Schering Pharma AgSubstituted oxazolidinones and their use in the field of blood coagulation
US7767702B2 (en)2001-06-202010-08-03Bayer Schering Pharma AktiengesellschaftSubstituted oxazolidinones for combinational therapy
US20100267685A1 (en)*2001-06-202010-10-21Bayer Schering Pharma AktiengesellschaftMethods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones
US20040242660A1 (en)*2001-06-202004-12-02Alexander StraubSubstituted oxazolidinones for combinational therapy
US20100081807A1 (en)*2003-01-072010-04-01Bayer Healthcare AgMethod for producing 5-cloro-n-(methyl)-2-thiophenecarboxamide
US8106192B2 (en)2003-01-072012-01-31Bayer Pharma AktiengesellschaftMethod for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
US9415053B2 (en)2003-11-272016-08-16Bayer Intellectual Property GmbhSolid, orally administrable pharmaceutical composition
US9402851B2 (en)2003-11-272016-08-02Bayer Intellectual Property GmbhProcess for the preparation of a solid, orally administrable pharmaceutical composition
US20090048173A1 (en)*2004-05-132009-02-19Wolfgang EisertUse Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors
US20070026065A1 (en)*2004-12-242007-02-01Bayer Healthcare AgSolid, modified-release pharmaceutical dosage forms which can be administered orally
US20090004265A1 (en)*2005-01-312009-01-01Bayer Healthcare AgPrevention and Treatment of Thromboembolic Disorders
US9539218B2 (en)2005-01-312017-01-10Bayer Intellectual Property GmbhPrevention and treatment of thromboembolic disorders
US20090036504A1 (en)*2005-09-232009-02-05Bayer Healthcare Ag2-Aminoethoxyacetic Acid Derivatives and Their Use
US7932278B2 (en)2005-09-232011-04-26Bayer Schering Pharma Aktiengesellschaft2-aminoethoxyacetic acid derivatives and their use
US8188270B2 (en)2005-10-042012-05-29Bayer Schering Pharma AktiengesellschaftPolymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
US20080306070A1 (en)*2005-10-042008-12-11Bayer Healthcare AgCombination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders
US8586082B2 (en)2005-10-042013-11-19Bayer Intellectual Property GmbhSolid orally administerable pharmaceutical dosage forms with rapid active principle release
US20100152189A1 (en)*2005-10-042010-06-17Bayer Healthcare AgNovel polymorphous form and the amorphous form of 5-chloro-n-({ (5s)-2-oxo-3[4-(3-oxo-4-morpholinyl(-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
US20100120718A1 (en)*2006-11-022010-05-13Bayer Schering Pharma AktiengesellschaftCombination therapy of substituted oxazolidinones
US7816355B1 (en)2009-04-282010-10-19Apotex Pharmachem IncProcesses for the preparation of rivaroxaban and intermediates thereof
US20100273798A1 (en)*2009-04-282010-10-28Apotex Pharmachem Inc.Processes for the preparation of rivaroxaban and intermediates thereof
US20100273790A1 (en)*2009-04-282010-10-28Apotex Pharmachem Inc.Processes for the preparation of rivaroxaban and intermediates thereof
US8101609B2 (en)2009-04-282012-01-24Apotex Pharmachem Inc.Processes for the preparation of rivaroxaban and intermediates thereof
CN102822167A (en)*2010-01-042012-12-12埃南蒂亚有限公司Process for the preparation of rivaroxaban and intermediates thereof
CN102753537A (en)*2010-02-102012-10-24桑多斯股份公司Method for the preparation of rivaroxaban
WO2012051692A1 (en)2010-10-182012-04-26Apotex Pharmachem Inc.Processes for the preparation of rivaroxaban and intermediates thereof
US9556163B2 (en)2011-05-062017-01-31Egis Gyogyszergyar Nyilvanosan Mukodo ReszvenytarsasagProcess for the preparation of a rivaroxaban and intermediates formed in said process
WO2013152168A1 (en)2012-04-062013-10-10Indiana University Research And Technology CorporationProcesses for preparing rivaroxaban
WO2013164833A1 (en)*2012-05-022013-11-07Symed Labs LimitedImproved process for preparing rivaroxaban using novel intermediates
CN104487436A (en)*2012-05-022015-04-01信谊实验室有限公司Improved process for preparing rivaroxaban using novel intermediates
US9376427B2 (en)2012-05-022016-06-28Symed Labs LimitedProcess for preparing rivaroxaban using intermediates
CN104487436B (en)*2012-05-022017-05-24信谊实验室有限公司Improved process for preparing rivaroxaban using intermediates
CN103864771A (en)*2012-12-132014-06-18北京京卫信康医药科技发展有限公司Rivaroxaban preparation method
CN103351385A (en)*2013-06-282013-10-16浙江燎原药业有限公司Preparation method for rivaroxaban intermediate
CN103524447A (en)*2013-10-242014-01-22山东铂源药业有限公司Method for synthesizing rivaroxaban intermediate 4-(4-aminophenyl)-3-molindone
CN103724336A (en)*2013-12-242014-04-16悦康药业集团有限公司Synthesis method of novel anticoagulation drug
US10106557B2 (en)2014-09-262018-10-23North China Pharmaceutical New Drug R&D Co., Ltd.Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof
KR20170055551A (en)*2014-09-262017-05-19놀스 차이나 파머수티컬 뉴 드럭 알앤디 씨오., 엘티디Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof
WO2016045586A1 (en)*2014-09-262016-03-31华北制药集团新药研究开发有限责任公司Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof
KR102485412B1 (en)2014-09-262023-01-05놀스 차이나 파머수티컬 뉴 드럭 알앤디 씨오., 엘티디Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof
CN109280053A (en)*2018-10-112019-01-29东南大学 Rivaroxaban oxazolidine impurity reference substance and preparation method thereof
WO2020101587A1 (en)2018-11-162020-05-22Santa Farma İlaç Sanayi̇ A.Ş.Oral formulations comprising rivaroxaban

Also Published As

Publication numberPublication date
ES2360097T3 (en)2011-05-31
JP4667044B2 (en)2011-04-06
EP1583761B1 (en)2011-02-23
DE50313496D1 (en)2011-04-07
JP2006513227A (en)2006-04-20
CA2512504C (en)2012-08-21
US20100081807A1 (en)2010-04-01
US8106192B2 (en)2012-01-31
WO2004060887A1 (en)2004-07-22
CA2512504A1 (en)2004-07-22
AU2003296728A1 (en)2004-07-29
DE10300111A1 (en)2004-07-15
EP1583761A1 (en)2005-10-12

Similar Documents

PublicationPublication DateTitle
US8106192B2 (en)Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
US7351823B2 (en)Preparation process
CN102753537B (en)Prepare the method for razaxaban
JP6325978B2 (en) Process for the preparation of rivaroxaban and intermediates formed in the process
US20150011756A1 (en)Process for preparation of rivaroxaban and intermediates thereof
EP3565552B1 (en)An improved process for the preparation of rivaroxaban involving novel intermediate
WO2012041263A2 (en)A method of manufacturing 2-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]- l,3-oxazolidin-5-yl}methyl)-lh-isoindol-l,3(2h)-dione with a high optical purity
JP2009518380A (en) Preparation of 2-chloroethoxy-acetic acid-N, N-dimethylamide
KR101811123B1 (en)Novel morpholine diphosphate salt, and method for manufacturing high purity rivaroxaban using same
US20170267669A1 (en)Process for the Preparation of Rivaroxaban
HK1103722B (en)Production method
KR101206598B1 (en) Manufacturing method
MXPA06007902A (en)Production method

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:BAYER HEALTHCARE, AG, GERMANY

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THOMAS, CHRISTIAN R.;REEL/FRAME:017717/0964

Effective date:20050609

ASAssignment

Owner name:BAYER SCHERING PHARMA AG, GERMANY

Free format text:MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:022520/0150

Effective date:20081230

Owner name:BAYER SCHERING PHARMA AG,GERMANY

Free format text:MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:022520/0150

Effective date:20081230

ASAssignment

Owner name:BAYER SCHERING PHARMA AG, GERMANY

Free format text:CORRECTION IN COVER SHEET PREVIOUSLY RECORDED;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:022575/0337

Effective date:20081230

Owner name:BAYER SCHERING PHARMA AG,GERMANY

Free format text:CORRECTION IN COVER SHEET PREVIOUSLY RECORDED;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:022575/0337

Effective date:20081230

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION


[8]ページ先頭

©2009-2025 Movatter.jp